| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Département d’Ingénierie et d’Etudes des Protéines, Commissariat à l’Energie Atomique-Saclay, Gif sur Yvette, France; and
Institut National de la Santé et de la Recherche Médicale U396, Hôpital St Louis, Paris, France
T cell epitopes containing peptides have been recently proposed as an alternative to conventional immunotherapy of allergic diseases because they are expected to be better tolerated than allergen extracts. A principal limitation to their clinical use is that they present an important diversity, which primarily results from the polymorphism of HLA class II molecules. In Caucasian populations, however, seven alleles of the most expressed molecules (namely DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301, and DRB1*1501) predominate. Peptides from allergens that would efficiently bind to them should be potential candidates for specific immunotherapy. In this paper, we have determined the peptides present in the major bee venom allergen by investigating the capacity of synthetic peptides that encompass its whole sequence to bind to each allele. Several efficient binders have been identified and are either allele-specific or common to several HLA-DR molecules. Interestingly enough, the 81–97 sequence is universal in the sense that it binds to all studied molecules. This sequence is surrounded by several active regions, which make the 76–106 sequence particularly rich of binding determinants and a good candidate for specific immunotherapy. Statistical analyses of the binding data also provide an overview of the preponderant HLA-DR alleles specificity.
This article has been cited by other articles:
|
|
 |
|
  X. Zhang, F. A. Castelli, X. Zhu, M. Wu, B. Maillere, and L. BenMohamed Gender-Dependent HLA-DR-Restricted Epitopes Identified from Herpes Simplex Virus Type 1 Glycoprotein D Clin. Vaccine Immunol., September 1, 2008; 15(9): 1436 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jahn-Schmid, P. Sirven, V. Leb, W. F. Pickl, G. F. Fischer, G. Gadermaier, M. Egger, C. Ebner, F. Ferreira, B. Maillere, et al. Characterization of HLA Class II/Peptide-TCR Interactions of the Immunodominant T Cell Epitope in Art v 1, the Major Mugwort Pollen Allergen J. Immunol., September 1, 2008; 181(5): 3636 - 3642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-F. Wang, J. Kerzerho, O. Adotevi, H. Nuyttens, C. Badoual, G. Munier, S. Oudard, S. Tu, E. Tartour, and B. Maillere Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients J. Immunol., July 1, 2008; 181(1): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Van Overtvelt, E. Wambre, B. Maillere, E. von Hofe, A. Louise, A. M. Balazuc, B. Bohle, D. Ebo, C. Leboulaire, G. Garcia, et al. Assessment of Bet v 1-Specific CD4+ T Cell Responses in Allergic and Nonallergic Individuals Using MHC Class II Peptide Tetramers J. Immunol., April 1, 2008; 180(7): 4514 - 4522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kudela, B. Janjic, J. Fourcade, F. Castelli, P. Andrade, J. M. Kirkwood, T. El-Hefnawy, M. Amicosante, B. Maillere, and H. M. Zarour Cross-Reactive CD4+ T Cells against One Immunodominant Tumor-Derived Epitope in Melanoma Patients J. Immunol., December 1, 2007; 179(11): 7932 - 7940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mouquet, S. Farci, P. Joly, B. Maillere, J. Leblond, L. Drouot, J. Leprince, M. C. Tonon, P. Loiseau, D. Charron, et al. A Truncated Alternative Spliced Isoform of Human Desmoglein 1 Contains a Specific T Cell Epitope Binding to the Pemphigus Foliaceus-Associated HLA Class II DRbeta1*0102 Molecule J. Immunol., November 1, 2006; 177(9): 6517 - 6526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Janjic, P. Andrade, X.-F. Wang, J. Fourcade, C. Almunia, P. Kudela, A. Brufsky, S. Jacobs, D. Friedland, R. Stoller, et al. Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers J. Immunol., August 15, 2006; 177(4): 2717 - 2727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Cohen, S. Pouvelle-Moratille, X.-F. Wang, S. Farci, G. Munier, D. Charron, A. Menez, M. Busson, and B. Maillere Scanning the HIV Genome for CD4+ T Cell Epitopes Restricted to HLA-DP4, the Most Prevalent HLA Class II Molecule J. Immunol., May 1, 2006; 176(9): 5401 - 5408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Monneaux, J. Hoebeke, C. Sordet, C. Nonn, J.-P. Briand, B. Maillere, J. Sibillia, and S. Muller Selective Modulation of CD4+ T Cells from Lupus Patients by a Promiscuous, Protective Peptide Analog J. Immunol., November 1, 2005; 175(9): 5839 - 5847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Immonen, S. Farci, A. Taivainen, J. Partanen, S. Pouvelle-Moratille, A. Narvanen, T. Kinnunen, S. Saarelainen, M. Rytkonen-Nissinen, B. Maillere, et al. T Cell Epitope-Containing Peptides of the Major Dog Allergen Can f 1 as Candidates for Allergen Immunotherapy J. Immunol., September 15, 2005; 175(6): 3614 - 3620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Immunotherapy Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S46 - S50. [Full Text] [PDF]
|
|
|
|
|
|
M. Mandic, F. Castelli, B. Janjic, C. Almunia, P. Andrade, D. Gillet, V. Brusic, J. M. Kirkwood, B. Maillere, and H. M. Zarour One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma J. Immunol., February 1, 2005; 174(3): 1751 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Buhot, A. Chenal, A. Sanson, S. Pouvelle-Moratille, M. H. Gelb, A. Menez, D. Gillet, and B. Maillere Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity Protein Sci., November 1, 2004; 13(11): 2970 - 2978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mandic, C. Almunia, S. Vicel, D. Gillet, B. Janjic, K. Coval, B. Maillere, J. M. Kirkwood, and H. M. Zarour The Alternative Open Reading Frame of LAGE-1 Gives Rise to Multiple Promiscuous HLA-DR-restricted Epitopes Recognized by T-helper 1-type Tumor-reactive CD4+ T Cells Cancer Res., October 1, 2003; 63(19): 6506 - 6515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Holtzman Drug Development for Asthma Am. J. Respir. Cell Mol. Biol., August 1, 2003; 29(2): 163 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fournel, S. Neichel, H. Dali, S. Farci, B. Maillere, J.-P. Briand, and S. Muller CD4+ T Cells from (New Zealand Black x New Zealand White)F1 Lupus Mice and Normal Mice Immunized Against Apoptotic Nucleosomes Recognize Similar Th Cell Epitopes in the C Terminus of Histone H3 J. Immunol., July 15, 2003; 171(2): 636 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, P. Chaux, V. Stroobant, A. M. M. Eggermont, J. Corthals, B. Maillere, K. Thielemans, M. Marchand, T. Boon, and P. van der Bruggen A MAGE-3 Peptide Presented by HLA-DR1 to CD4+ T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein J. Immunol., July 1, 2003; 171(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jacquemin, V. Vantomme, C. Buhot, R. Lavend'homme, W. Burny, N. Demotte, P. Chaux, K. Peerlinck, J. Vermylen, B. Maillere, et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A Blood, February 15, 2003; 101(4): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Castelli, C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Segard, J.-G. Guillet, A. Menez, B. Georges, et al. HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity J. Immunol., December 15, 2002; 169(12): 6928 - 6934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Zarour, B. Maillere, V. Brusic, K. Coval, E. Williams, S. Pouvelle-Moratille, F. Castelli, S. Land, J. Bennouna, T. Logan, et al. NY-ESO-1 119-143 Is a Promiscuous Major Histocompatibility Complex Class II T-Helper Epitope Recognized by Th1- and Th2-Type Tumor-reactive CD4+ T Cells Cancer Res., January 1, 2002; 62(1): 213 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.B. Kay Allergy and Allergic Diseases- Second of Two Parts N. Engl. J. Med., January 11, 2001; 344(2): 109 - 113. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
